PVR and chronic myelogenous leukemia, BCR-ABL1 positive: We assessed and found that the majority of K562 CML (78.5%), MOLM14 AML (99.5%), U937 AML (99.9%), MV4;11 AML (94.8%), SK-BR-3 metastatic breast adenocarcinoma (94.1%) and SK-OV-3 ovarian adenocarcinoma cells (99.2%) were CD155+, while levels of CD111 expression varied widely with tumor type: 0.14% (hardly detectable) of K562, 12.1% of MOLM14, 89.7% of U937, 13.8% of MV4;11, 89.5% of SK-BR-3, and 18.2% of SK-OV-3 cells were CD111+ (Figure 2A).